1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol has been researched along with sirolimus in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomez, O; Le, M; Molina-Holgado, E; Molina-Holgado, F; Sanchez-Caro, C; Sanchez-Rodriguez, A | 1 |
1 other study(ies) available for 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol and sirolimus
| Article | Year |
|---|---|
Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.
Topics: Animals; Arachidonic Acids; Cannabinoids; Cell Differentiation; Cells, Cultured; Chromones; Dronabinol; Enzyme Activators; Indoles; Morpholines; Myelin Proteins; Oligodendroglia; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Signal Transduction; Sirolimus; Stem Cells; TOR Serine-Threonine Kinases | 2011 |